Hepatitis C Positive Antibody Test Leads to Molecular Assay
|
By LabMedica International staff writers Posted on 18 Jan 2016 |

Image: Histopathology of chronic viral hepatitis C, necrosis and inflammation are prominent (Photo courtesy of University of Utah).
Conventional laboratory and medical practice for Hepatitis C virus infection involves referring a patient for a second office visit and blood draw if the initial antibody screening test produces a positive result.
A hepatitis C screening test identifies viral antibodies while a molecular test identifies viral ribonucleic acid (RNA) when the infection is active. In some people, the immune system clears hepatitis C infection on its own, but antibodies may linger in the blood for decades. As a result, a positive antibody screening test can signify resolved or active infection, and as much as 3% of antibody screens produce a false positive.
Quest Diagnostics (Madison, NJ, USA) will automatically perform molecular testing on all patient specimens whose antibody screening results indicate Hepatitis C virus infection, and remove standalone positive antibody screening as a test option. The change to the company’s service menu eliminates the prospect a patient may receive a positive screening result but fail to undergo additional molecular testing, as recommended by medical guidelines, to help confirm a diagnosis of active hepatitis C infection, the cause of chronic hepatitis C.
With the change to the Quest menu, any specimen that an antibody screening test indicates is positive will automatically reflex to molecular testing. Pricing for the screen and molecular tests are the same as before; positive screening results will reflex to molecular testing automatically and be charged the additional molecular test fee. Early diagnosis, through laboratory blood tests, and treatment can help prevent liver damage, cirrhosis, liver cancer and death.
Rick L. Pesano, MD, PhD, vice president of development, science and innovation at Quest Diagnostics, said, “This change to Quest's test offerings is medically responsible and appropriate. It closes a gap in current hepatitis C care by reducing the possibility a patient will undergo multiple office visits and blood draws or be inappropriately referred to specialists based on incomplete testing. With this change to our offering, we will help more people receive insights they can use to access effective treatment and ultimately lead healthier lives.”
Related Links:
Quest Diagnostics
A hepatitis C screening test identifies viral antibodies while a molecular test identifies viral ribonucleic acid (RNA) when the infection is active. In some people, the immune system clears hepatitis C infection on its own, but antibodies may linger in the blood for decades. As a result, a positive antibody screening test can signify resolved or active infection, and as much as 3% of antibody screens produce a false positive.
Quest Diagnostics (Madison, NJ, USA) will automatically perform molecular testing on all patient specimens whose antibody screening results indicate Hepatitis C virus infection, and remove standalone positive antibody screening as a test option. The change to the company’s service menu eliminates the prospect a patient may receive a positive screening result but fail to undergo additional molecular testing, as recommended by medical guidelines, to help confirm a diagnosis of active hepatitis C infection, the cause of chronic hepatitis C.
With the change to the Quest menu, any specimen that an antibody screening test indicates is positive will automatically reflex to molecular testing. Pricing for the screen and molecular tests are the same as before; positive screening results will reflex to molecular testing automatically and be charged the additional molecular test fee. Early diagnosis, through laboratory blood tests, and treatment can help prevent liver damage, cirrhosis, liver cancer and death.
Rick L. Pesano, MD, PhD, vice president of development, science and innovation at Quest Diagnostics, said, “This change to Quest's test offerings is medically responsible and appropriate. It closes a gap in current hepatitis C care by reducing the possibility a patient will undergo multiple office visits and blood draws or be inappropriately referred to specialists based on incomplete testing. With this change to our offering, we will help more people receive insights they can use to access effective treatment and ultimately lead healthier lives.”
Related Links:
Quest Diagnostics
Latest Immunology News
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
- Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
- Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
- Luminescent Probe Measures Immune Cell Activity in Real Time
- Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
- Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients
- Companion Diagnostic Test for CRC Patients Identifies Eligible Treatment Population
- Novel Tool Uses Deep Learning for Precision Cancer Therapy
- Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients
- Novel Multiplex Assay Supports Diagnosis of Autoimmune Vasculitis
- Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer
- Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients
- Novel Gene Signature Predicts Immunotherapy Response in Advanced Kidney Cancers
- New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response
- AI Model Accurately Predicts MSI Tumor and Immune Checkpoint Inhibitor Responsiveness
Channels
Clinical Chemistry
view channel
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more
Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read moreMolecular Diagnostics
view channel
New Diagnostic Method Detects Pneumonia at POC in Low-Resource Settings
Pneumonia continues to be one of the leading causes of death in low- and middle-income countries, where limited access to advanced laboratory infrastructure hampers early and accurate diagnosis.... Read more
Blood Immune Cell Analysis Detects Parkinson’s Before Symptoms Appear
Early diagnosis of Parkinson’s disease remains one of the greatest challenges in neurology. The condition, which affects nearly 12 million people globally, is typically identified only after significant... Read moreHematology
view channel
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read moreImmunology
view channel
Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read more
Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
Modern cancer immunotherapies rely on the ability of CD8⁺ T cells to rapidly multiply within tumors, generating the immune force needed to eliminate cancer cells. However, the biological triggers behind... Read morePathology
view channel
New Molecular Analysis Tool to Improve Disease Diagnosis
Accurately distinguishing between similar biomolecules such as proteins is vital for biomedical research and diagnostics, yet existing analytical tools often fail to detect subtle structural or compositional... Read more
Tears Offer Noninvasive Alternative for Diagnosing Neurodegenerative Diseases
Diagnosing and monitoring eye and neurodegenerative diseases often requires invasive procedures to access ocular fluids. Ocular fluids like aqueous humor and vitreous humor contain valuable molecular information... Read moreTechnology
view channel
Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement
Sorting different cell types—such as cancerous versus healthy or live versus dead cells—is a critical task in biology and medicine. However, conventional methods often require labeling, chemical exposure,... Read more
Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
Blood tests remain a cornerstone of medical diagnostics, but traditional imaging and analysis methods can be slow, costly, and reliant on dyes or contrast agents. Now, scientists have developed a real-time,... Read moreIndustry
view channel
Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
QIAGEN (Venlo, Netherlands) has entered into a definitive agreement to fully acquire Parse Biosciences (Seattle, WA, USA), a provider of scalable, instrument-free solutions for single-cell research.... Read more
Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
Puritan Medical Products (Guilford, ME, USA), the world’s most trusted manufacturer of swabs and specimen collection devices, is set to exhibit at AMP2025 in Boston, Massachusetts, from November 11–15.... Read more
Advanced Instruments Merged Under Nova Biomedical Name
Advanced Instruments (Norwood, MA, USA) and Nova Biomedical (Waltham, MA, USA) are now officially doing business under a single, unified brand. This transformation is expected to deliver greater value... Read more








